Iron complex compounds for subcutaneous use in therapy of iron deficiency in companion animals
A subcutaneous iron oligoisomaltose or octasaccharide complex addresses the lack of effective parenteral iron drugs for companion animals by rapidly replenishing iron stores and improving hemoglobin levels, offering a safe and efficient treatment for iron deficiency anemia.
US20260108551A1Pending Publication Date: 2026-04-23PHARMACOSMOS HLDG AS
View PDF 0 Cites 0 Cited by
Patent Information
- Authority / Receiving Office
- US · United States
- Patent Type
- Applications(United States)
- Current Assignee / Owner
- PHARMACOSMOS HLDG AS
- Filing Date
- 2022-08-03
- Publication Date
- 2026-04-23
Smart Images
Figure US20260108551A1-D00000_ABST
Abstract
The present invention relates to iron complex compounds for subcutaneous use in a method of therapy, e.g., for iron deficiency, particularly of iron deficiency anaemia, in a companion animal and to pharmaceutical compositions for subcutaneous administration, comprising an iron complex compound and a pharmaceutically acceptable carrier. The present invention relates more particularly, although not exclusively, to iron octasaccharide complexes, pharmaceutical compositions comprising an iron octasaccharide complex, and the iron octasaccharide complexes for use in a method of therapy of iron deficiency, particularly of iron deficiency anaemia, in a human or non-human subject.
Need to check novelty before this filing date? Find Prior Art